NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Neoleukin Therapeutics Inc (NASDAQ: NLTX)
NLTX Technical Analysis
5
As on 9th Jun 2023 NLTX STOCK Price closed @ 0.78 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.66 & Strong Sell for SHORT-TERM with Stoploss of 3.58 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NLTXSTOCK Price
Open | 0.79 | Change | Price | % |
High | 0.80 | 1 Day | -0.01 | -1.27 |
Low | 0.78 | 1 Week | -0.02 | -2.50 |
Close | 0.78 | 1 Month | -0.09 | -10.34 |
Volume | 54500 | 1 Year | -4.14 | -84.15 |
52 Week High 5.52 | 52 Week Low 0.40 |
NASDAQ USA Most Active Stocks
TSLA | 244.40 | 4.06% |
TTOO | 0.07 | -12.50% |
SOFI | 8.18 | 0.74% |
FFIE | 0.33 | 6.45% |
PONO | 1.72 | 2.38% |
AMD | 124.92 | 3.20% |
IDEX | 0.06 | 0.00% |
NKLA | 0.70 | 14.75% |
AMZN | 123.43 | -0.66% |
AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
NLTX Daily Charts |
NLTX Intraday Charts |
Whats New @ Bazaartrend |
NLTX Free Analysis |
|
NLTX Important Levels Intraday
RESISTANCE | 0.82 |
RESISTANCE | 0.81 |
RESISTANCE | 0.80 |
RESISTANCE | 0.79 |
SUPPORT | 0.77 |
SUPPORT | 0.76 |
SUPPORT | 0.75 |
SUPPORT | 0.74 |
NLTX Forecast May 2024
4th UP Forecast | 4.21 |
3rd UP Forecast | 3.11 |
2nd UP Forecast | 2.43 |
1st UP Forecast | 1.75 |
1st DOWN Forecast | -0.19 |
2nd DOWN Forecast | -0.87 |
3rd DOWN Forecast | -1.55 |
4th DOWN Forecast | -2.65 |
NLTX Weekly Forecast
4th UP Forecast | 2.59 |
3rd UP Forecast | 2.01 |
2nd UP Forecast | 1.65 |
1st UP Forecast | 1.29 |
1st DOWN Forecast | 0.27 |
2nd DOWN Forecast | -0.09 |
3rd DOWN Forecast | -0.45 |
4th DOWN Forecast | -1.03 |
NLTX Forecast2024
4th UP Forecast | 11.01 |
3rd UP Forecast | 7.73 |
2nd UP Forecast | 5.7 |
1st UP Forecast | 3.67 |
1st DOWN Forecast | -2.11 |
2nd DOWN Forecast | -4.14 |
3rd DOWN Forecast | -6.17 |
4th DOWN Forecast | -9.45 |
Neoleukin Therapeutics Inc ( NASDAQ USA Symbol : NLTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NLTX Other Details
Segment | EQ | |
Market Capital | 290611936.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
NLTX Address
NLTX Latest News
NLTX Business Profile
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Address: 1616 Eastlake Avenue East, Seattle, WA, United States, 98102
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service